Patient characteristics by arm
| . | E coli–asparaginase no. (%) of patients N = 354 (100%) . | Erwinia-asparaginase no. (%) of patients N = 346 (100%) . |
|---|---|---|
| Sex | ||
| Male | 206 (58) | 202 (58) |
| Female | 148 (42) | 144 (42) |
| Age (y) | ||
| Younger than 1 | 10 (3) | 11 (3) |
| 1 through 9 | 282 (80) | 275 (80) |
| 10 through 17 | 62 (17) | 60 (17) |
| ALL | 334 (94) | 319 (92) |
| WBC count (109/L) | ||
| Less than 25 | 215 (64) | 201 (63) |
| 25 to 100 | 66 (20) | 69 (22) |
| At least 100 | 53 (16) | 49 (15) |
| CNS involvement | 17 (5) | 15 (5) |
| Immunophenotype | ||
| B lineage | 289 (87) | 267 (84) |
| T lineage | 45 (13) | 52 (16) |
| Karyotype | ||
| Successful examinations | 261 (78) | 235 (74) |
| Hyperdiploidy | 70 [27]* | 52 [22]* |
| t(9;22) | 3 [1]* | 11 [5]* |
| t(4;11) | 5 [2]* | 6 [3]* |
| Near-haploidy | 1 [< 1]* | 1 [< 1]* |
| Normal and others | 182 [70]* | 165 [70]* |
| Response to prephase: blasts (/μL) on D8 | ||
| Less than 1000 | 292 (87) | 278 (87) |
| 1000 | 42 (13) | 41 (13) |
| Initial very-high risk features | 47 (14) | 54 (17) |
| NCI risk groups | ||
| NCI standard risk | 212 (63) | 203 (64) |
| NCI high risk | 122 (36) | 116 (36) |
| Lymphoblastic lymphoma | 20 (6) | 27 (8) |
| Murphy stage III or IV | 20 (100) | 23 (85) |
| T lineage | 19 (95) | 22 (81) |
| . | E coli–asparaginase no. (%) of patients N = 354 (100%) . | Erwinia-asparaginase no. (%) of patients N = 346 (100%) . |
|---|---|---|
| Sex | ||
| Male | 206 (58) | 202 (58) |
| Female | 148 (42) | 144 (42) |
| Age (y) | ||
| Younger than 1 | 10 (3) | 11 (3) |
| 1 through 9 | 282 (80) | 275 (80) |
| 10 through 17 | 62 (17) | 60 (17) |
| ALL | 334 (94) | 319 (92) |
| WBC count (109/L) | ||
| Less than 25 | 215 (64) | 201 (63) |
| 25 to 100 | 66 (20) | 69 (22) |
| At least 100 | 53 (16) | 49 (15) |
| CNS involvement | 17 (5) | 15 (5) |
| Immunophenotype | ||
| B lineage | 289 (87) | 267 (84) |
| T lineage | 45 (13) | 52 (16) |
| Karyotype | ||
| Successful examinations | 261 (78) | 235 (74) |
| Hyperdiploidy | 70 [27]* | 52 [22]* |
| t(9;22) | 3 [1]* | 11 [5]* |
| t(4;11) | 5 [2]* | 6 [3]* |
| Near-haploidy | 1 [< 1]* | 1 [< 1]* |
| Normal and others | 182 [70]* | 165 [70]* |
| Response to prephase: blasts (/μL) on D8 | ||
| Less than 1000 | 292 (87) | 278 (87) |
| 1000 | 42 (13) | 41 (13) |
| Initial very-high risk features | 47 (14) | 54 (17) |
| NCI risk groups | ||
| NCI standard risk | 212 (63) | 203 (64) |
| NCI high risk | 122 (36) | 116 (36) |
| Lymphoblastic lymphoma | 20 (6) | 27 (8) |
| Murphy stage III or IV | 20 (100) | 23 (85) |
| T lineage | 19 (95) | 22 (81) |
Percentages were computed on successful cytogenetic examinations. NCI risk groups were as defined by the consensus conference.